APA (7th ed.) Citation

Darb-Esfahani, S., Denkert, C., Stenzinger, A., Salat, C., Sinn, B., Schem, C., . . . Loibl, S. (2016). Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 7(42), 67686-67698. https://doi.org/10.18632/oncotarget.11891

Chicago Style (17th ed.) Citation

Darb-Esfahani, Silvia, et al. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated with Neoadjuvant Anthracycline/taxane-based Chemotherapy." Oncotarget 7, no. 42 (2016): 67686-67698. https://doi.org/10.18632/oncotarget.11891.

MLA (9th ed.) Citation

Darb-Esfahani, Silvia, et al. "Role of TP53 Mutations in Triple Negative and HER2-positive Breast Cancer Treated with Neoadjuvant Anthracycline/taxane-based Chemotherapy." Oncotarget, vol. 7, no. 42, 2016, pp. 67686-67698, https://doi.org/10.18632/oncotarget.11891.